Why the study?
Can in vitro-in vivo extrapolation (IVIVE) accurately predict the pharmacokinetic and pharmacodynamic (QTc) effects of quinidine in humans?
Can in vitro-in vivo extrapolation (IVIVE) accurately predict the pharmacokinetic and pharmacodynamic (QTc) effects of quinidine in humans?
Answers are grounded in this paper and cite their sources.
Mechanistic in vitro-in vivo extrapolation can reliably predict clinical QTc prolongation from preclinical in vitro data, offering a potential method to reduce animal testing in cardiac safety evaluation.
The translational sciences aim to transfer results from basic research to the treatment of animals or patients. One of the approaches that could be utilized to achieve this goal is the in vitro-in vivo extrapolation (IVIVE) of pharmacokinetic (PK) and pharmacodynamic (PD) properties using in silico methods. Such methodology, if properly applied, could help substantially reduce the use of animals in pre-clinical research. Here, quinidine was chosen as an example of a drug with cardiac effects and results of nine published clinical studies describing its PK (plasma concentration) and PD (QTcB/?QTcB) effects were mimicked by combination of the IVIVE platform Simcyp (pharmacokinetics prediction) with the ToxComp (cardiac effect prediction) system, based exclusively on in vitro data. The results show that reliable QT prediction is possible using the mechanistic IVIVE of the PK and PD effects. This can be considered a proof-of-concept that also could be applied as a drug safety evaluation procedure.
No takes yet. Share an insight, caveat, or question.
Sebastian Polak (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: